Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Biochemical Reagents >  Antibiotic >  mutacin 1140

mutacin 1140

Basic information Safety Supplier Related

mutacin 1140 Basic information

Product Name:
mutacin 1140
Synonyms:
  • MU1140
  • L-Cysteinamide, L-phenylalanyl-L-lysyl-D-cysteinyl-L-tryptophyl-2,3-didehydroalanyl-L-leucyl-L-cysteinyl-(2S)-2-amino-3-mercaptobutanoyl-L-prolylglycyl-L-cysteinyl-L-alanyl-L-arginyl-(2Z)-2-amino-2-butenoylglycyl-D-cysteinyl-L-phenylalanyl-L-asparaginyl-D-cysteinyl-L-tyrosyl-N-[(1Z)-2-mercaptoetheny...
  • L-Cysteinamide, L-phenylalanyl-L-lysyl-D-cysteinyl-L-tryptophyl-2,3-didehydroalanyl-L-leucyl-L-cysteinyl-(2S)-2-amino-3-mercaptobutanoyl-L-prolylglycyl-L-cysteinyl-L-alanyl-L-arginyl-(2Z)-2-amino-2-butenoylglycyl-D-cysteinyl-L-phenylalanyl-L-asparaginyl-D-cysteinyl-L-tyrosyl-N-[(1Z)-2-mercaptoethenyl]-, cyclic (3→7),(8→11),(16→213),(19→211)-tetrakis(thioether)
  • mutacin 1140
CAS:
218133-96-1
MF:
C103H138N28O23S4
MW:
2264.64
Mol File:
218133-96-1.mol
More
Less

mutacin 1140 Chemical Properties

Density 
1.53±0.1 g/cm3(Predicted)
pka
9.90±0.15(Predicted)
More
Less

mutacin 1140 Usage And Synthesis

Description

Mutacin 1140 (Mu1140) is a potent antibiotic against Gram-positive bacteria, such as Staphylococcus aureus. The antibiotic is produced by the oral bacterium Streptococcus mutans and is a member of the epidermin family of type AI lantibiotics. [1]

Biosynthesis

The biosynthesis of mutacin 1140 shares some important features with the biosynthesis of other lantibiotic systems; however, there are considerable differences between the biosynthesis of mutacin 1140 and nisin. Mutacin 1140 biosynthesis is a dynamic process in which PTM enzyme modifications and transport are occurring in a highly coordinated fashion, supporting the hypothesis that leader peptide binding at a single locus is sufficient for coordinating PTM enzyme modifications and transport.

Biological Functions

Mu1140 analogs were shown to be more effective than currently available treatments for systemic and skin MRSA infections. Further, the study clearly shows that the new analogs are superior to native Mu1140 for the treatment of a systemic MRSA infection.

Structure and conformation

The four lanthionine rings are labeled A, B, C, and D. The lipid II binding domain consists of rings A and B, while the lateral assembly domain consists of the hinge region (residues 12 to 15) and rings C and D. Protease-susceptible residues Lys and Arg are shown in blue and represent the sites for the alanine substitutions in the Mu1140 analogs. The amino acid abbreviations Dha is dehydroalanine and Dhb is dehydrobutyrine. The labels AlaS and SAla signifying the residues involved in the lanthionine ring formation, AlaS (Dha), AbuS (aminobutyric acid), and SAla (Cys).

References

[1] MIN JU. Evaluation of analogs of mutacin 1140 in systemic and cutaneous methicillin-resistant Staphylococcus aureus infection models in mice.[J]. Frontiers in Microbiology, 2022, 13: 1067410. DOI:10.3389/fmicb.2022.1067410.

mutacin 1140Supplier

BOC Sciences
Tel
16314854226; +16314854226
Email
inquiry@bocsci.com